Mouse Transplantation Immunity Depressed by Trichinella Spiralis

Svet-Moldavsky, GeorgeJ.; Shaghijan, GenriettaSh.; Mkheidze, D. M.; Litovchenko, TatjanaA.; Ozeretskovskaya, N. N.; Kadaghidze, ZairaG.; Chernyakhovskaya, InessaYu.

doi:10.1016/s0140-6736(69)90078-6

Cited by 7 publications

(12 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of the live infection therapies, administration of N. brasiliensis showed the most significant prolongation of graft survival (34). However, overall, across all studies the largest increase to allograft survival was seen with the administration of a recombinant protein derived from P. westermani, which showed an extension of allograft survival 86 days beyond that seen in the control animals (control: 18 ± 0.5, treatment: 104 ± 33, p < 0.05) (29).…”

Section: Therapeutic Differences Between Live and Product-based Helmimentioning

confidence: 92%

“…The minimum improvement to graft survival of 2.1 days was observed with the administration of an extract isolated from 100 mg of T. spiralis larvae within a skin graft model (31). The maximum improvement to graft survival was 86 days in a skin graft model involving the administration of 30 µg/kg of neutral thiol protease isolated from P. westermani (29). Entries show study types differing by treatment type (live vs. helminth extract/secretion), and administration timeframe relative to transplantation.…”

Section: Allograft Survivalmentioning

confidence: 97%

“…(24, 26-28, 30, 32, 34, 36, 37) and product-based (n = 2) (29, 33) treatment, with four studies investigating the difference between live and product-based intervention (23,25,31,35). Within these publications, product based therapeutics were defined as soluble worm extracts (n = 5) (23,25,29,35), native secretions from the worm (n = 1) (23), or purified recombinant proteins (n = 1) (33). Administration of these therapies was given as intraperitoneal (n = 4) (24,29,32,36), oral intubation/probe (n = 5) (23,(26)(27)(28)37), and subcutaneous injection (n = 3) (33-35).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Within these publications, product based therapeutics were defined as soluble worm extracts (n = 5) (23,25,29,35), native secretions from the worm (n = 1) (23), or purified recombinant proteins (n = 1) (33). Administration of these therapies was given as intraperitoneal (n = 4) (24,29,32,36), oral intubation/probe (n = 5) (23,(26)(27)(28)37), and subcutaneous injection (n = 3) (33-35). One publication did not clearly define administration (30), whilst two other publications used a combination of oral/intraperitoneal injection (25) or intraperitoneal/subcutaneous injection (31).…”

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Effectiveness of Helminth Therapy in the Prevention of Allograft Rejection: A Systematic Review of Allogeneic Transplantation

et al. 2020

View full text Add to dashboard Cite

Background: The unique immunomodulatory capacity of helminth parasites has been investigated as a novel strategy in the prevention of allograft rejection after transplantation. This review was conducted to fully evaluate the specific effects of helminth therapy on allograft survival reported in published studies of animal models of allogeneic transplantation. Method: Following PRISMA protocol guidelines, a literature search was conducted using PubMed, MEDLINE via OvidSP, along with additional manual searches of selected reference lists. Publications describing helminth intervention within allograft transplantation models were screened for relevance to eligibility criteria. Primary and secondary outcomes were extracted using standardized data collection tables. The SYRCLE risk of bias assessment tool was used for quality assessment. Due to heterogeneity of study designs, meta-analysis could not be performed; rather outcomes are presented as a narrative synthesis with concept mapping. This review was registered in PROSPERO with ID: CRD42018097175. Results: The literature search generated 1,443 publications, which after screening for relevance to the eligibility criteria yielded 15 publications for qualitative analysis. All 15 publications reported improvement to allograft survival as a result of helminth therapy. This prolonged allograft survival was not significantly different when helminth-derived products were used compared to live infection. However, the extent of positive impact on allograft survival was noted to be dependent on study design factors, such as the chronicity of the live helminth infection, allograft type and the species/genus of helminth selected. Conclusion: Both live and product-based helminth therapy have potential applications as novel immune regulators or adjuncts for the prevention of allograft rejection. However, there were differences in efficacy between different worms and preparations of worm-derived products. Therefore, further studies are required to determine the most appropriate worm for a specific allograft, to elucidate the optimal dose and route of administration, and to better understand the modulation of immune responses that can mediate tolerance.

show abstract

Section: Therapeutic Differences Between Live and Product-based Helmimentioning

confidence: 92%

Section: Allograft Survivalmentioning

confidence: 97%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Effectiveness of Helminth Therapy in the Prevention of Allograft Rejection: A Systematic Review of Allogeneic Transplantation

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Working in an area of endemic infection, Greenwood (1968) observed that autoimmune diseases were relatively rare in the human population, and suggested that massive stimulation of the patient's immune responses by parasites, especially malaria, was in some way responsible. There is also a report that infections of Trichinella spiralis in mice may reduce immunity to skin grafts (Svet-Moldavsky et al, 1969). There is also a report that infections of Trichinella spiralis in mice may reduce immunity to skin grafts (Svet-Moldavsky et al, 1969).…”

Section: Suggestions For Future Workmentioning

confidence: 99%

Immunity: Host Response

1970

The Journal of Parasitology

View full text Add to dashboard Cite

Trichinella spiralis infection changes immune response in mice performed abdominal heterotopic cardiac transplantation and prolongs cardiac allograft survival time

Deng

Yao

et al. 2015

Parasitol Res

View full text Add to dashboard Cite

Allograft rejection has been an obstacle for long-term survival of patients for many years. Current strategies for transplant rejection are not as optimal as we expected, especially for long-term treatments. Trichinella spiralis, a nematode parasitized in mammalian muscle and as an invader, maintains harmonious with host in the long term by evading host immune attack. To determine whether T. spiralis infection impacts on allograft rejection, we performed mice cardiac allograft transplantation model by using BALB/c (H-2(b)) mice as donors and C57BL/6 (H-2(b)) mice orally infected with 300 muscle larvae for 28 days as recipients. Graft survival was monitored by daily palpation of the abdomen; histologic change was observed by H&E stain; and CD4(+), CD8(+), CD4(+)IFN-γ(+), and CD4(+)IL-17(+) T cells and regulatory T cells were examined with the use of flow cytometry. Serum cytokine levels were measured by Luminex. Finally, we found that mean survival time of cardiac allografts in T. spiralis group was 23.40 ± 1.99 days, while the vehicle control group was 10.60 ± 0.75 days. Furthermore, we observed alleviated histological changes in the heart allograft, decreased corresponding CD8(+) T cells, suppressed Th1 and Th17 responses, and increased regulatory T cell frequency in a murine cardiac transplantation model at day 7 post-transplantation in experimental group. These data suggest that T. spiralis infection resulted in prolonged allograft survival following murine cardiac transplantation, with suppressed Th1/Th17 responses and augmented regulatory T cells.

show abstract

Mouse Transplantation Immunity Depressed by Trichinella Spiralis

Cited by 7 publications

References 5 publications

Effectiveness of Helminth Therapy in the Prevention of Allograft Rejection: A Systematic Review of Allogeneic Transplantation

Effectiveness of Helminth Therapy in the Prevention of Allograft Rejection: A Systematic Review of Allogeneic Transplantation

Immunity: Host Response

Trichinella spiralis infection changes immune response in mice performed abdominal heterotopic cardiac transplantation and prolongs cardiac allograft survival time

Contact Info

Product

Resources

About